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Abstract 
Aims. The objectives of the present study were to describe epidemiology and outcomes in ambulatory heart failure 
(HF) patients stratified by left ventricular ejection fraction (LVEF) and to identify predictors for mortality at 1 year in 
each group. 
Methods and results. The European Society of Cardiology Heart Failure Long‐Term Registry is a prospective, 
observational study collecting epidemiological information and 1‐year follow‐up data in 9134 HF patients. Patients 
were classified according to baseline LVEF into HF with reduced EF [EF <40% (HFrEF)], mid‐range EF [EF 40–
50% (HFmrEF)] and preserved EF [EF >50% (HFpEF)]. In comparison with HFpEF subjects, patients with HFrEF 
were younger (64 years vs. 69 years), more commonly male (78% vs. 52%), more likely to have an ischaemic 
aetiology (49% vs. 24%) and left bundle branch block (24% vs. 9%), but less likely to have hypertension (56% vs. 
67%) or atrial fibrillation (18% vs. 32%). The HFmrEF group resembled the HFrEF group in some features, 
including age, gender and ischaemic aetiology, but had less left ventricular and atrial dilation. Mortality at 1 year 
differed significantly between HFrEF and HFpEF (8.8% vs. 6.3%); HFmrEF patients experienced intermediate rates 
(7.6%). Age, New York Heart Association (NYHA) class III/IV status and chronic kidney disease predicted mortality 
in all LVEF groups. Low systolic blood pressure and high heart rate were predictors for mortality in HFrEF and 
HFmrEF. A lower body mass index was independently associated with mortality in HFrEF and HFpEF patients. 
Atrial fibrillation predicted mortality in HFpEF patients. 
Conclusions. Heart failure patients stratified according to different categories of LVEF represent diverse phenotypes 
of demography, clinical presentation, aetiology and outcomes at 1 year. Differences in predictors for mortality might 
improve risk stratification and management goals. 
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Introduction 
Although the survival of patients with chronic heart failure (HF) has improved with the introduction 
of disease‐modifying therapies, these patients still have a substantial risk for death or recurrent 
decompensation requiring hospitalization.
1, 2
 
 
Left ventricular ejection fraction (LVEF) has an essential role in phenotyping and guiding the therapy 
of patients with chronic HF.
3
 Until recently, two types of HF patient were clinically distinguished based 
on assessment of LVEF, comprising, respectively, those with HF with reduced ejection fraction (HFrEF) 
and those with HF with preserved ejection fraction (HFpEF). The specific EF thresholds used to define 
these HF entities have differed considerably even in recent clinical trials, community‐based studies and 
HF registries.
4, 5
 HFrEF has been generally defined according to an EF of <40%, whereas the specific EF 
thresholds for the definition of HFpEF have varied from >40% to >50%. By defining a cut‐off for HFpEF 
that is higher than that used to define the HFrEF population, a ‘grey zone’ of EF between 40% and 50% 
remains to be further characterized.
6
 This group was formally recognized in the recent 2016 European 
Society of Cardiology (ESC) guidelines as representing a distinct phenotype, termed HF with mid‐range 
EF (HFmrEF).
3 
 
Heart failure registries
7
 and community‐based studies8 have systematically excluded HFmrEF, or 
usually included patients with this condition in the HFpEF group, and therefore specific therapeutic 
evidence for this group of patients is lacking.
3 
 
The ESC HF Long‐Term (ESC‐HF‐LT) Registry is the largest pan‐European cohort providing 
contemporary generalizable information about ‘real‐world’ chronic HF patients in the full spectrum of 
EF, from all regions of Europe and from Mediterranean countries.
9, 10 
  
In the present manuscript we describe and compare for the first time the clinical epidemiology, 
treatment patterns and long‐term outcomes in ambulatory HF patients stratified by LVEF category 
according to the 2016 ESC guidelines and identify specific independent predictors for mortality at 1 year 
in each group. 
Methods 
Study design and clinical setting 
The ESC‐HF‐LT Registry is an ongoing, prospective, multinational, multicentre, observational study 
of patients presenting to cardiology centres in European and Mediterranean countries.
9 
Site selection in 
each participating country was performed by national co‐ordinators (supplementary material online, 
Appendix S1) and targeted a sample of centres of different sizes and levels of complexity from which 
patients were recruited, focusing on capturing a broad spectrum of cardiology and HF specialty units 
regularly following outpatients with HF.  
Inclusion criteria 
All outpatients with HF seen at the clinics were included during the enrolment period. To facilitate 
consecutive enrolment, patients were enrolled in the registry on a one‐day‐per‐week basis in Phase 1, and 
then on five consecutive days per season in Phase 2, and five consecutive working days between 
1 October and 31 December in Phase 3. A follow‐up visit at 12 months after the entry visit was mandatory 
for all patients in order to allow information on morbidity and mortality to be collected. The follow‐up 
clinical visit could be replaced by a telephone call if the patient was unable to travel to the clinical centre. 
During the course of the year patients were followed up according to the usual practice of the respective 
centres. 
 
There were no specific exclusion criteria other than patient age, which was required to be higher than 
18 years. Echocardiographic assessment of LVEF was performed at enrolment in the registry unless the 
patient presented with recent echocardiographic data (obtained within the previous week). 
 
The ESC‐HF‐LT Registry was approved by the respective local institutional review boards according 
to the rules of each participating country. No data were collected before detailed information had been 
provided to the patient and signed informed consent had been obtained. 
Participating centres 
Patients were enrolled at centres in the following countries and regions: Lithuania and Sweden 
(northern countries); Bosnia and Herzegovina, Bulgaria, the Czech Republic, Hungary, Latvia, Poland, 
Romania and Slovakia (eastern countries); Austria and France (western countries); Greece, Italy, 
Portugal, Serbia, Slovenia, Spain and Turkey (southern countries); Israel (Middle East), and Egypt (North 
Africa). 
 
Several training meetings were organized for national co‐ordinators and study investigators to assure 
consistency in data collection among participating centres. 
 
Furthermore, in each participating country, data sources were subjected to verification for a random 
sample of 5% of enrolled patients, by EURObservational Research Programme (EORP) monitors. 
  
Statistical analysis 
All results were summarized overall and then stratified by LVEF (EF <40%, EF 40–50%, EF >50%). 
 
Baseline continuous variables were reported as the mean ± standard deviation (SD) or as the median 
and interquartile range (IQR), as appropriate. Among‐group comparisons were made using a non‐
parametric test (Kruskal–Wallis test). Categorical variables were reported as percentages and compared 
using a χ2 test or Fisher's exact test if any expected cell count was less than 5. For categorical variables 
with more than two possible values, exact P‐values were estimated according to the Monte Carlo method. 
Univariate analysis was applied to both continuous and categorical variables. In addition, for all‐cause 
death at 1 year, a pairwise comparison was performed among the three LVEF categories.  
 
The outcomes were time to death from any cause, time to admission to hospital for worsening HF, and 
a composite of time to all‐cause death or HF hospitalization from the date of enrolment to 1 year of 
follow‐up. 
 
Plots of Kaplan–Meier curves for time to all‐cause death, time to admission to hospital for HF and 
time to all‐cause death or HF hospitalization for the three EF categories were made and survival 
distributions compared using the log‐rank test. Subsequently, the association between EF group and the 
three outcomes was assessed in the overall cohort using univariable and multivariable Cox analyses. 
 
All variables at entry that were statistically significant in univariable analysis by EF group (P < 0.10), 
and variables considered to be of relevant clinical interest as fixed covariates were included in the 
multivariable model (Cox model) to identify the predictors for all‐cause death from study entry to follow‐
up at 1 year in the overall cohort, taking into account EF group. A significance level of 0.05 was required 
to allow a variable both to be entered into and to stay in the multivariable model.  
 
Finally, to identify independent predictors for all‐cause death, separately in the three EF subgroups, 
three separate multivariable Cox analyses were performed. All variables at entry (supplementary material 
online, Appendix S2) that were statistically significant in univariable analysis (P < 0.10), and variables 
considered to be of relevant clinical interest were included in the multivariable model (Cox model) to 
identify the independent predictors for all‐cause death from study entry to follow‐up at 1 year, separately 
for subgroups of patients with LVEF of <50%, LVEF of 40–50%, and LVEF of >50%, respectively. A 
significance level of 0.05 was required to allow a variable both to be entered into and to stay in the 
multivariable model. As we were assessing associations between a broad range of baseline variables and 
outcomes, no specific interaction was tested. Missing values were not imputed.  
 
A two‐sided P‐value of <0.05 was considered to indicate statistical significance. All analyses were 
performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA).  
Results 
From April 2011 to January 2015, a total of 16 354 patients were enrolled in the ESC‐HF‐LT 
Registry. These included 9428 outpatients and 6926 hospitalized patients. 
 
Of the 9428 ambulatory patients, 294 patients (3.1%) had no available LVEF data and were not 
included in the present analysis. The remaining 9134 patients are characterized in the present manuscript. 
Echocardiography was performed at enrolment in the registry in 91.8% of patients. The remaining 8.2% 
of patients had undergone a recent echocardiographic examination. 
 
The number of patients lost to follow‐up at 1 year was 230 (2.4% of 9428). 
  
Overall, 59.8% of HF patients were classified as having HFrEF, 24.2% as having HFmrEF and 16.0% 
as having HFpEF. Classification by geographical region and the distribution of patients by deciles of EF 
are shown in Figure 1.  
 
 
 
Figure 1. (A) Geographic distribution of 9134 heart failure patients stratified by ejection fraction (EF). 
(B) Distribution of patients by deciles of EF.  
At enrolment in the registry, baseline characteristics, in terms of demography, clinical characteristics, 
aetiologies and co‐morbidities in patients with chronic HF stratified by EF are presented in Table 1. 
  
Table 1. Baseline characteristics in chronic heart failure patients stratified by ejection fraction 
 
All  
(n = 9134)  
EF <40%  
(n = 5460)  
EF 40–50%  
(n = 2212)  
EF >50%  
(n = 1462)  
P‐value  
      
Geographic distribution, n (%)       
Eastern 1607 (17.6) 1014 (18.6) 384 (17.4) 209 (14.3)  
Northern 665 (7.3) 444 (8.1) 151 (6.8) 70 (4.8)  
Southern 5174 (56.6) 2995 (54.8) 1226 (55.4) 953 (65.2)  
Western 721 (7.9) 492 (9.0) 148 (6.7) 81 (5.5)  
North Africa 559 (6.1) 227 (4.2) 255 (11.5) 77 (5.3)  
Middle East 408 (4.5) 288 (5.3) 48 (2.2) 72 (4.9)  
Age, years, mean ± SD 64.8 ± 13.3 64.0 ± 12.6 64.2 ± 14.2 68.6 ± 13.7 <0.001 
Age ≥75 years, % 25.7 21.9 26.4 38.9 <0.001 
Female gender, % 28.2 21.6 31.5 47.9 <0.001 
BMI, kg/m2, mean ± SD  28.1 ± 5.1 27.8 ± 4.9 28.6 ± 5.4 28.4 ± 5.4 <0.001 
SBP, mmHg, mean ± SD 124.3 ± 20.8 121.6 ± 20.0 126.5 ± 21.1 130.98 ± 21.4 <0.001 
SBP ≤110 mmHg, % 30.3 34.4 27.0 19.9 <0.001 
Heart rate, b.p.m., mean ± SD 72.9 ± 15.4 72.9 ± 15.1 73.2 ± 15.9 72.5 ± 15.5 0.344 
Heart rate ≥70 b.p.m., % 55.7 56.4 55.6 53.5 0.108 
NYHA class III/IV, % 26.0 30.6 18.4 20.3 <0.001 
Pulmonary congestion, % 74.4 74.5 71.7 77.5 0.031 
Peripheral congestion, % 28.4 29.4 26.0 29.0 0.002 
Peripheral hypoperfusion, % 3.2 3.9 2.7 1.8 <0.001 
HF history with previous hospitalization, % 47.4 47.1 48.1 47.4 0.774 
HF diagnosis >12 months, % 61.8 58.9 67.4 64.7 <0.001 
Primary aetiology, %      
Ischaemic heart disease 42.9 48.6 41.8 23.7 <0.001 
Hypertension 7.9 4.5 9.6 18.1 <0.001 
Hypertension treatment 58.5 55.6 60.1 67.0 <0.001 
Idiopathic dilated cardiomyopathy 29.5 35.1 27.6 11.6 <0.001 
Valve disease 8.2 4.4 10.0 19.5 <0.001 
Tachycardia‐related cardiomyopathy 1.4 1.1 1.5 2.4 <0.001 
Other 8.4 6.1 8.4 17.0 <0.001 
PCI, % 25.4 29.4 23.5 13.4 <0.001 
CABG, % 13.6 15.3 12.3 9.2 <0.001 
CRT, % 13.3 18.1 8.4 3.5 <0.001 
CRT‐D, % 13.6 22.4 6.2 2.2 <0.001 
ICD, % 24.8 34.8 13.4 5.3 <0.001 
Valvular surgery, % 8.8 7.3 8.8 14.7 <0.001 
Smoker, % 11.5 12.7 10.7 8.1 <0.001 
Diabetes mellitus, % 31.4 32.3 30.5 29.3 0.058 
COPD, % 14.1 15.2 11.6 14.0 <0.001 
Sleep apnoea, % 5.2 5.1 5.1 5.5 0.857 
Prior stroke/TIA, % 9.2 9.4 8.3 9.8 0.249 
Chronic kidney disease,a %  18.8 19.5 16.5 19.9 0.006 
Hepatic dysfunction, % 3.5 3.9 3.0 2.8 0.039 
Depression, % 7.4 7.2 7.1 8.6 0.161 
ECG performed, % 94.8 94.7 94.6 95.2 0.659 
Sinus rhythm, % 62.4 62.8 64.4 57.8 <0.001 
Atrial fibrillation, % 21.5 18.3 22.3 32.2 <0.001 
Table 1. Baseline characteristics in chronic heart failure patients stratified by ejection fraction 
 
All  
(n = 9134)  
EF <40%  
(n = 5460)  
EF 40–50%  
(n = 2212)  
EF >50%  
(n = 1462)  
P‐value  
QT duration, ms, mean ± SD 410.1 ± 56.3 417.5 ± 55.3 398.2 ± 59.9 402.1 ± 50.3 <0.001 
LBBB, % 19.5 24.2 15.4 8.7 <0.001 
LVH, % 31.7 25.9 34.6 48.2 <0.001 
EF, %, mean ± SD 37.6 ± 13.5 29.1 ± 7.6 44.0 ± 5.3 59.7 ± 7.7 <0.001 
LVEDD, mm, mean ± SD 61.0 ± 16.1 64.9 ± 17.5 58.0 ± 8.4 51.1 ± 14.4 <0.001 
LA volume, mL, mean ± SD 73.7 ± 46.0 79.7 ± 48.8 60.1 ± 35.7 78.3 ± 51.2 <0.001 
MV inflow pattern‐restrictive (E/A > 2), % 35.4 39.6 28.0 31.4 <0.001 
Mitral regurgitation moderate–severe, % 31.2 35.6 28.4 19.5 <0.001 
Aortic stenosis moderate–severe, % 3.7 2.8 3.4 7.3 <0.001 
Aortic regurgitation moderate–severe, % 4.7 4.1 5.7 5.0 0.015 
Tricuspid regurgitation moderate–severe, % 19.2 19.5 17.8 20.3 0.164 
Mean pulmonary artery systolic pressure, mmHg, 
mean ± SD 
29.1 ± 12.1 30.2 ± 11.7 25.4 ± 10.7 29.5 ± 14.5 <0.001 
      
 
BMI, body mass index; CABG, coronary artery bypass graft; COPD, chronic pulmonary obstructive disease; CRT, cardiac 
resynchronization therapy; CRT‐D, CRT with defibrillation; ECG, electrocardiogram; EF, ejection fraction; ICD, implantable 
cardioverter defibrillator; LA, left atrium; LBBB, left bundle branch block; LVEDD, left ventricular end‐diastolic diameter; LVH, 
left ventricular hypertrophy; MV, mitral valve; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; 
SBP, systolic blood pressure; SD, standard deviation; TIA, transient ischaemic attack. 
a Chronic kidney disease: baseline creatinine >1.5 mg/dL.  
The subset of patients with EF of >50% included an older population and 48.0% were female. In 
contrast, patients presenting with EF of <40% and those with EF of 40–50% were on average 4 years 
younger and more frequently male. 
 
The aetiology of HF was ischaemic in a higher percentage of patients with HFrEF and HFmrEF, 
whereas hypertension was more common in those with HFpEF. 
 
At enrolment, systolic blood pressure (SBP) was lower in patients with HFrEF, whereas heart rate 
(HR) did not differ significantly among EF categories. Pulmonary congestion was seen in similar 
proportions of HFrEF and HFpEF patients (74.5% and 77.5%, respectively), but New York Heart 
Association (NYHA) class was higher in HFrEF patients, 30.6% of whom presented with NYHA class III 
or IV status. A lower body mass index (BMI) was reported in patients with HFrEF compared with HFpEF 
patients. 
 
Rates of most other non‐cardiac associated conditions did not vary significantly among the EF groups, 
except for chronic obstructive pulmonary disease (COPD), and hepatic and renal dysfunction, which were 
more frequent in the group with HFrEF. 
 
Routine measurements at baseline are presented in the supplementary material online (Table S1). The 
only clinically significant difference referred to levels of natriuretic peptides, which were higher in 
patients with HFrEF.  
 
Electrocardiography was performed in 94.8% of study patients. Atrial fibrillation (AF) on ECG was 
most commonly seen in patients with HFpEF (32.2%) (Table 1). The proportion of patients with left 
bundle branch block (LBBB) was higher in the HFrEF group (24.2%).  
  
Left ventricular diameter was larger in HFrEF than in HFpEF patients. The proportion of patients with 
LVH was lower in the HFrEF group than in the other EF subgroups. Left atrial volume was smaller in 
patients with HFmrEF compared with patients with HFrEF or HFpEF. Mitral regurgitation was 
commonly seen in the HFrEF group and the proportion of patients with aortic valve disease was higher in 
the HFpEF group (Table 1).  
 
Pharmacological therapy of chronic HF patients at the completion of outpatient visits and at 1 year is 
presented in Figure 2. In patients with HFrEF, ACE inhibitors/ARBs, beta‐blockers and 
mineralocorticoid receptor antagonists (MRAs) were used in 91.7%, 92.9% and 67.8% of subjects, 
respectively. Similar rates of utilization of guideline‐directed medical therapies (GDMTs) were observed 
in HFmrEF patients, whereas lower rates were noted in patients with HFpEF. The rate of utilization of 
GDMTs did not change significantly during the follow‐up, regardless of EF category.  
 
 
 
Figure 2. Pharmacological treatments administered in 9134 heart failure patients at entry and at 1 year of follow‐up according to 
ejection fraction (EF) category. ACE, angiotensin‐converting enzyme; ARBs, angiotensin receptor blockers; BB, beta‐blockers; 
MRAs, mineralocorticoid receptor antagonists. 
Outcomes at 1 year 
Table 2 presents the events (mortality, causes of death and hospitalizations) experienced through the 
1‐year follow‐up. Mortality rates at 1 year were 8.8% in patients with HFrEF, 7.6% in patients with 
HFmrEF and 6.4% in patients with HFpEF. By pairwise comparison, HFrEF patients had a significantly 
higher mortality rate than HFpEF patients (P = 0.0002), whereas all‐cause mortality in HFmrEF did not 
differ significantly from mortality in HFrEF (P = 0.07) or in HFpEF (P = 0.17). Non‐cardiovascular 
mortality was numerically higher in patients with HFmrEF and HFpEF (27.8% and 30.7%, respectively, 
vs. 20.1% in HFrEF) (Table 2). The percentages of patients hospitalized for HF in the HFrEF, HFmrEF 
and HFpEF groups were 14.6%, 8.7% and 9.7%, respectively. Combined incidences of death and 
hospitalization for HF at 1 year were 21.2% in HFrEF patients, 15.0% in HFmrEF patients and 14.6% in 
HFpEF patients. Figure S1 (supplementary material online) presents rates of these outcomes by deciles of 
EF. Figures 3 4 and 5 show Kaplan–Meier curves for all‐cause mortality, hospitalization for HF and the 
composite event of all‐cause mortality and hospitalization for HF stratified by LVEF.  
Table 2. Outcomes at 1 year by category of ejection fraction 
 
All  
(n = 9134)  
EF <40%  
(n = 5460)  
EF 40–50%  
(n = 2212)  
EF >50%  
(n = 1462)  
P‐valuea  
      
All‐cause death, % 8.1 8.8 7.6 6.3 0.005 
Cardiovascular death, % 52.1 53.5 50.6 47.2 0.504 
Non‐cardiovascular death, % 23.2 20.1 27.8 30.7 0.059 
Unknown, % 24.7 26.3 21.6 21.9 0.393 
All‐cause hospitalization, % 28.1 31.9 22.0 23.5 <0.001 
HF hospitalization, % 12.4 14.6 8.7 9.7 <0.001 
All‐cause death or HF hospitalization, % 18.6 21.2 15.0 14.6 <0.001 
      
 
EF, ejection fraction; HF, heart failure. 
a P‐values for differences among EF <40%, EF 40–50% and EF >50%.  
 
 
 
Figure 3. Kaplan–Meier curves for all‐cause mortality in 9134 heart failure patients at 1 year. EF, ejection 
fraction. 
  
 
 
 
Figure 4. Kaplan–Meier curves for hospitalization for heart failure in 9134 heart failure patients at 1 year. 
EF, ejection fraction. 
 
 
 
Figure 5. Kaplan–Meier curves for all‐cause mortality or hospitalization for heart failure in 9134 heart 
failure patients at 1 year. EF, ejection fraction. 
 
  
Although not included in the present analysis, high rates of adverse outcomes at 1 year were observed 
in patients for whom information about EF was not available, including a mortality rate of 11.4% at 1 
year, a rate of hospitalization for HF of 9.5% at 1 year, and a mortality/hospitalization for HF rate of 
20.1% at 1 year. 
 
Variables independently associated with all‐cause mortality at 1 year are shown in Table 3. Older age, 
NYHA class and chronic kidney disease were independently associated with a worse outcome regardless 
of EF category. Low SBP and high HR were predictors for mortality in patients with reduced and mid‐
range EF. A higher BMI was independently associated with lower mortality in HFrEF and HFpEF 
patients. Atrial fibrillation was an independent predictor of mortality in HFpEF patients. Other non‐
cardiovascular co‐morbidities, such as depression, peripheral artery disease and hepatic dysfunction, were 
predictive of mortality at 1 year in different categories of EF.  
Table 3. Predictors for all‐cause mortality within 1 year by ejection fraction category 
Variables 
EF <40%  
OR (95% CI) 
P‐value  
EF 40–50%  
OR (95% CI) 
P‐value  
EF >50%  
OR (95% CI) 
P‐value  
       
Age 1.026 (1.017–1.035) <0.0001 1.035 (1.021–1.049) <0.0001 1.021(1.012–1.029) 0.021 
Sex (ref = male) — — 0.587 (0.393–0.877) 0.0094 — — 
Body mass index 0.958 (0.937–0.979) 0.0001 — — 0.938 (0.896–0.983) 0.0071 
Systolic blood pressure 0.983 (0.978–0.988) <0.0001 0.977 (0.968–0.985) <0.0001 — — 
Heart rate 1.007 (1.001–1.012) 0.0276 1.011 (1.001–1.020) 0.0316 — — 
NYHA class III/IV 2.023 (1.664–2.459) <0.0001 1.840 (1.296–2.611) 0.0006 2.722 (1.746–4.244) <0.0001 
Ischaemic heart disease — — 3.120(1.604–6.068) 0.0008 — — 
Pulmonary congestion — — — — 0.993 (0.989–0.998) 0.0049 
S3 gallop 1.437 (1.076–1.918) 0.0140 — — — — 
Mitral regurgitation — — 1.721 (1.240–2.388) 0.0012 — — 
Aortic stenosis 1.886 (1.288–2.761) 0.0011 — — 2.144 (1.261–3.647) 0.0049 
Diabetes 1.419 (1.160–1.735) 0.0007 — — — — 
Atrial fibrillation — — — — 2.158 (1.360–3.422) 0.0011 
Peripheral artery disease 1.422 (1.115–1.815) 0.0046 — — 3.234 (1.947–5.371) <0.0001 
Chronic kidney disease 1.781 (1.452–2.185) <0.0001 1.601 (1.108–2.314) 0.0122 1.981 (1.251–3.136) 0.0035 
Hepatic dysfunction — — 2.370 (1.282–4.381) 0.0059 — — 
Depression 1.504 (1.113–2.032) 0.0078 — — — — 
       
 
CI, confidence interval; EF, ejection fraction; NYHA, New York Heart Association; OR, odds ratio. 
 
Discussion 
The ESC‐HF‐LT Registry provides a contemporary dataset based on which chronic HF patients with 
different categories of EF, as suggested by the 2016 ESC guidelines,
3 
can be evaluated. One important 
finding of the present study is that chronic HF patients stratified by categories of EF (i.e. <40%, 40–50%, 
>50%) represent different phenotypes in terms of demography, clinical presentation, aetiology, 
mechanical and electrical remodelling, and pharmacotherapies. Furthermore, the registry provides 
important information regarding outcomes at 1 year and independent predictors for mortality in patients 
stratified by EF.  
  
In an ambulatory cardiology setting, the majority of HF patients present with HFrEF. The proportion 
of patients with HFpEF in our study is lower than those reported in other community‐based studies of 
HF,
8, 11-13
 but similar to that reported in a recent meta‐analysis.14 The study population distribution across 
the deciles of EF shows a unimodal distribution that peaks at EF of 30–40%, indicating a substantial 
proportion of patients in the ‘middle band’ of EF of 40–50%, and relatively few patients with an EF of 
>50%. This unimodal pattern of distribution is similar to that found in one HF trial
15 
and in observational 
studies enrolling chronic HF patients presenting routinely at ambulatory visits.
2
 In contrast, studies 
including hospitalized patients,
7 
or a mixed population of hospitalized patients and chronic HF patients 
included post‐discharge,11, 12 described a bimodal distribution, with substantial proportions of patients 
with HFrEF and HFpEF, and very few patients with HFmrEF. One possible explanation for this 
difference refers to the inclusion of a younger and predominantly male population in studies with 
unimodal distribution in comparison with studies showing a bimodal distribution. Other possible 
explanations for the lower proportion of HFpEF patients refer to the study methodology. The ESC‐HF‐LT 
Registry included only patients from cardiology departments or specialized HF units that care mostly for 
HFrEF patients. Patients with HFpEF commonly present with worsening non‐cardiac co‐morbidities and 
are more likely to be admitted and followed in internal medicine or geriatric wards.  
Phenotypes of left ventricular ejection fraction 
In the present study, patients with HFrEF were typically younger than patients with HFpEF, which 
confirms previously reported age differences between the two categories.
7, 8, 11, 12, 15
 Men were more likely 
to present with HFrEF, which is also consistent with previous studies.
13
 An ischaemic aetiology was more 
commonly reported in HFrEF than in HFpEF, whereas hypertension, diabetes and AF were more 
prevalent in HFpEF. Although congestion was seen in similar proportions of HFrEF and HFpEF patients, 
its clinical presentation, including NYHA class and hypotension, was more severe in HFrEF patients. 
Additionally, natriuretic peptide levels were higher in HFrEF than in HFpEF patients.  
 
Chamber dilation seen in HFrEF
16
 is coupled with pathological electric remodelling, including a 
longer QT interval and more frequent LBBB than in the other EF subgroups.  
 
The rate of use of GDMTs was high at the entry visit and did not change during the follow‐up. The 
ESC‐HF‐LT Registry demonstrates excellent adherence to guidelines and reduces the gap between the 
information generated by randomized controlled trials and those provided by observational research that 
reflects routine clinical practice.
9 
 
Compared with those with HFrEF, patients with HFpEF had high prevalences of hypertension, 
diabetes and AF, but were less likely to have ischaemic heart disease. Because HFpEF is a disease that 
affects elderly people, it coexists with a high frequency of co‐morbidities. As these may mimic HF 
symptoms, this may generate concern for the possible misdiagnosis of HF when EF is preserved. 
However, in the current study, frequencies of co‐morbid conditions were similar in patients with HFpEF 
and HFrEF. Therefore, it is unlikely that HF‐like symptoms were caused by other conditions, such as 
COPD or renal failure, more often among patients with preserved compared with those with reduced EF. 
The pattern of ventricular remodelling in HFpEF is characterized by normal left ventricular size and a 
high prevalence of LVH. Left atrial dilation and high prevalence of AF suggest predominantly left atrial 
electrical remodelling. 
 
Although no guideline‐specific recommendations exist for this group of patients, substantial 
proportions of HFpEF patients are treated with beta‐blockers, ACE/ARBs and MRAs, and, as in HFrEF 
patients, these treatments remain stable over time. 
  
In the ESC‐HF‐LT Registry, the mid‐range group has many features more typical of HFrEF. Patients 
with HFmrEF were younger, more likely to be male, more frequently had coronary artery disease and less 
frequently had hypertension compared with those with HFpEF. Left ventricular end‐diastolic diameters 
were higher in HFmrEF subjects compared with those with HFpEF, but lower than in patients with 
HFrEF. 
 
Similarities between HFrEF and HFmrEF suggest that HFmrEF represents either recovered HFrEF or 
early‐stage HFrEF,17, 18 but the lack of serial echocardiograms in the present study prohibits more 
granular insight.  
 
The HFmrEF group may have comprised patients with early‐stage HFrEF who recover EF, or well 
treated patients with disease of ischaemic aetiology in which EF changes were delayed, patients who had 
recovered after myocarditis and HFpEF patients with a progressive decline in EF.
6 
 
The proportions of patients with previous CRT implants were 8.4% in the HFmrEF group and 3.5% in 
the HFpEF group, a finding that is highly suggestive of the benefit of the intervention and the dynamic 
change in LVEF from HFrEF at the time of implant, to HFmrEF or HFpEF at enrolment in the registry. 
 
Echocardiography follow‐up is crucial because a substantial proportion of HF patients may show 
dynamic changes in LVEF over time, especially those with disease of an ischaemic aetiology,
19, 20
 and 
patients may transition from one category to another. Unfortunately, the ESC‐HF‐LT Registry does not 
include echocardiography follow‐up, which is essential to determine the clinical course of chronic HF, 
especially in the subgroup with HFmrEF.  
 
Of note, previous HF clinical trials and epidemiological studies have systematically either excluded 
HFmrEF or mixed HFmrEF subjects within the HFpEF group. Hence, specific therapeutic evidence for 
this group of patients is lacking and current guidelines recommend that HFmrEF should be treated 
similarly to HFrEF.
3
 
Outcomes at 1 year 
In the ESC‐HF‐LT Registry, the rate of all‐cause mortality at 1 year was 8.1%; 52.1% of these deaths 
were attributable to cardiovascular causes. The figure is similar to that observed in the ESC‐HF pilot 
study (7.2%) and in the Italian Registry (5.9%).
1, 2
 The rate of HF hospitalization at 1 year was 28.2%, but 
of all admissions, only 44.1% were attributable to HF, which underscores the importance of non‐cardiac 
co‐morbidities in the general process of decompensation.  
 
Patients with HFpEF had a lower risk for adverse cardiovascular outcomes than those with HFrEF. 
The results contrast with those of other studies that report similar mortality rates in patients with HFpEF 
and HFrEF.
7, 8, 11
 Of note, all of these studies included patients hospitalized for HF and followed up post‐
discharge and thus refer to populations that differ from that of the ESC‐HF‐LT Registry, which enrolled 
chronic HF patients who presented routinely at outpatient visits. Similarly to the ESC‐HF‐LT Registry, in 
the CHARM (Candesartan in Heart Failure Reduction in Mortality) programme, patients with an EF of 
>45% were found to have a much lower risk for mortality at 1 year than those with reduced EF.
15
 In a 
recent meta‐analysis of data derived from 31 studies that included both registries and randomized 
controlled trials, patients with HFpEF were found to have a lower risk for death within 1 year compared 
with those with HFrEF (12.1% vs. 14.1%), irrespective of gender, age, ischaemic aetiology, hypertension, 
diabetes and AF.
21 
 
In patients with HFmrEF, the rate of mortality at 1 year lies between rates in the HFrEF and HFpEF 
groups. In terms of all adverse outcomes at 1 year, findings in the HFmrEF group resembled those of the 
HFpEF group more closely than those of the HFrEF group, an observation similar to those of previous 
reports.
15 
  
Although not included in the present analysis, patients for whom information about EF was missing 
showed the highest rate of mortality at 1 year, similar to that reported in a recent meta‐analysis.14 A higher 
index of non‐cardiovascular co‐morbidities, especially COPD, as well as the lower prescription of 
GDMTs than in patients with known EF, may explain the increased mortality in this subgroup.
14
 
Predictors for mortality at 1 year 
Overall, predictors for mortality in chronic HF outpatients were represented by variables that are 
easily accessible in clinical practice, including demographic factors, vitals, coexisting severe valvular 
disease and co‐morbidities. Older age, NYHA class III or IV status and chronic kidney disease were 
predictive of mortality at 1 year regardless of EF stratification, a finding similar to those observed in 
previous studies.
22, 23 
 
A lower SBP, higher HR and lower BMI were associated with increased mortality at 1 year in patients 
with HFrEF. Interestingly, although HR extends its predictive value in patients with EF 40–50%, beyond 
the EF cut‐off used in one clinical trial,24 it has not emerged as a predictor in the subgroup of patients with 
EF >50%, which suggests that targeting HR in this category may not be beneficial.
25, 26 
This is explained 
by recently reported differences in the prognostic role of HR according to EF. When EF is reduced, HR is 
a risk factor, and when EF is preserved, HR is simply a marker of the underlying pathological condition. 
Reducing it may be useful in terms of decreasing symptoms, but not in terms of prognostic 
improvement.
25 
 
In patients with HFrEF or HFpEF, a lower BMI identifies a particularly high risk for death within 1 
year. This observation is consistent with that previously reported in chronic HF patients.
27 
 
Ischaemic aetiology was associated with a poor prognosis in the HFmrEF subgroup. Significant mitral 
regurgitation as a consequence or cause of left ventricular remodelling was associated with higher 
mortality at 1 year in HFmrEF patients. Mitral regurgitation is a well‐known predictor of mortality in a 
wide spectrum of EF patients and, additionally, may overestimate EF in patients with borderline EF.
28 
 
Depression, peripheral artery disease and hepatic dysfunction were predictive of mortality in some 
chronic HF patients, an observation that emphasizes the need to identify non‐cardiac co‐morbidities in 
chronic HF patients.
22, 23 
Outpatients with HF should be included in multidisciplinary programmes, in 
which regular follow‐up in which data about vitals, clinical presentation, aetiologies and co‐morbidities 
are collected may improve prognosis.
3
 
Limitations 
The study population included only patients seen at cardiology outpatient clinics and did not include 
patients with chronic HF seen in other ambulatory facilities or those seen by other professionals such as 
internists. The diagnosis of HF was not centrally validated and cause of death was not adjudicated by a 
central committee. 
 
Echocardiography was performed in the context of routine clinical practice and, for this reason, was 
limited to a focused assessment of cardiac structure and function. 
 
In the present study, LVEF was obtained only at the moment of enrolment in the registry, and LVEF 
data from previous hospitalizations or at first diagnosis were not collected. 
 
The assessment of LVEF could not be standardized and therefore may have been subject to variations 
among different operators that may have resulted in the misclassification of some patients. Other 
potentially important variables, which may have prognostic importance, such as levels of natriuretic 
peptides, were not selected in the multivariate model as data were not available in many patients.  
Conclusions 
Chronic HF patients stratified by different categories of EF (i.e. <40%, 40–50% and >50%) represent 
different phenotypes in terms of demography, clinical presentation, aetiology, and mechanical and 
electrical remodelling. However, classifying chronic HF patients in ambulatory settings is more complex 
than simply stratifying patients by LVEF cut‐off values because these patients have a high burden of 
cardiovascular and non‐cardiovascular co‐morbidities, which may interact on different levels of LVEF 
and may influence prognosis more than LVEF category. 
 
Risk stratification and the identification of predictors of worse outcomes may provide opportunities to 
explore potential interactions between underlying risk and possible treatment effects, especially in EF 
categories in which guideline‐based recommendations are lacking. 
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